DefiniGEN strengthens Board with the appointment of Professor Sir John Savill

Cambridge, UK, 10th September 2018 -- DefiniGEN, the world leader in human iPSC differentiation and disease modelling, today announces the appointment of Professor Sir John Savill as a Non-Executive Director of the Board. Sir John will bring his expertise in translational science to DefiniGEN enabling the company to accelerate the development of new products and services which can improve the efficiency and economics of drug development. 

Sir John Savill was previously the Chief Executive of the Medical Research Council (MRC) in the UK. Within this role he was responsible to UK Parliament for expenditure of approximately £800 million per year as MRC’s Accounting Officer. Alongside the MRC role, Savill was also Vice-Principal and Head of the College of Medicine at the University of Edinburgh. As a renowned expert in research and innovation, Sir John will aid DefiniGEN in further developing its partnerships with the pharmaceutical and biomedical communities.

Dr Marcus Yeo, Chief Executive Officer, commented: “I am delighted to welcome John to the DefiniGEN board. With his extensive experience as a highly-regarded clinician and scientist I am confident that John will prove to be highly valuable as DefiniGEN continues to grow internationally in key markets.”

Sir John Savill stated: “DefiniGEN is one of the UK’s most innovative translational science companies providing valuable tools for biomedical research. I’m delighted to join the board at this important stage in the company’s development.

 

ENDS

Notes to Editors:

Photo: Professor Sir John Savill, Non-Executive Director DefiniGEN.

For a high-resolution image please contact lorna.cuddon@zymecommunications.com

 

For further information please contact:

Lorna Cuddon

Zyme Communications

Email: lorna.cuddon@zymecommunications.com

Tel: +44 (0) 7811 996 942

 

To opt-out from receiving press releases from Zyme Communications please email info@zymecommunications.com. To view our privacy policy, please click here.

About DefiniGEN Ltd http://www.definigen.com/

DefiniGEN was founded in 2013 to commercialise OptiDIFF, the stem cell production platform developed at the University of Cambridge, UK. The Company has world-leading expertise in the area of iPSC-derived human cell production and metabolic disease modelling. The application of these technologies in drug discovery provides pharmaceutical companies with more predictive in vitro cell products enabling the development of safer and more effective treatments. In addition, the technology platform utilises fully defined and humanised conditions required for the development of regenerative medicine cellular therapies. DefiniGEN builds on intellectual property and knowledge resident at the University of Cambridge Regenerative Medicine Department at Addenbrooke’s Hospital and has in-licensed the Nobel prize-winning Yamanaka induced pluripotent stem cell IP portfolio from iPS Academia Japan Inc.

 

 

 

Back to news